Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study of SI-613 in Patients with Enthesopathy(Japan. Phase II)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 May 2023 According to a Seikagaku Corporation media release, in February 2022, development of SI-613-ETP was discontinued since primary efficacy endpoint was not met, and the Company will prioritize identification of the cause of shock or anaphylaxis of JOYCLE.
12 May 2023 Status changed from active, no longer recruiting to discontinued, according to a Seikagaku Corporation media release.
10 Oct 2018 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com